Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Externally Developed Products Mean Bigger Revenues, But Not In Diabetes

Executive Summary

External innovation directly links to commercial success for big pharma, and will continue to do so until 2026, according to a new report by Datamonitor Healthcare.

You may also be interested in...



Lilly Pays KeyBioscience $55m Up Front to Expand Its Early Diabetes Pipeline

Lilly nabbed multiple molecules for its early-stage diabetes portfolio via a $55m-plus partnership with KeyBioscience, making sure that the big pharma's pipeline continues to add products to its largest franchise.

Sanofi, Google’s Verily Enter Diabetes JV To Produce Joined Up Solutions

Sanofi’s diabetes head says French drug maker’s JV pact with Google’s Verily will combine novel therapies for the condition with cutting edge technologies to produce better focused, outcome-based combinations.

Funding The Future: Accelerating The Long Walk To Innovation

In Vivo spoke with two company creators working in the biotech industry about their strategies for seeking new science and their funding philosophy when building the biotechs of tomorrow.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC123250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel